Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dosimetry in a myeloablative setting.

Hazel Breitz1

  • 1NeoRx Corporation, 410 W. Harrison, Seattle, WA 98119, USA. hbbreitz@neorx.com

Cancer Biotherapy & Radiopharmaceuticals
|March 28, 2002
PubMed
Summary

High-dose systemic radioactivity for cancer treatment can cause bone marrow ablation. This review examines radiation dose estimates in these studies to improve patient treatment and minimize toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2007
Same author

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Cancer biotherapy & radiopharmaceuticals·2005
Same author

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2005
Same author

Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.

Cancer biotherapy & radiopharmaceuticals·2005
Same author

Dosimetry model for radioactivity localized to intestinal mucosa.

Cancer biotherapy & radiopharmaceuticals·2004
Same author

Clinical aspects of radiation nephropathy.

Cancer biotherapy & radiopharmaceuticals·2004

Area of Science:

  • Medical Physics
  • Oncology
  • Radiology

Background:

  • High-dose systemic radiotherapy is used for cancer treatment.
  • Myeloablation (bone marrow damage) can occur due to targeted radiation.
  • Accurate dosimetry is crucial for safe and effective treatment.

Purpose of the Study:

  • To review studies on internally administered high-dose radiation therapy.
  • To examine reported radiation absorbed dose estimates to the bone marrow and other organs.

Main Methods:

  • Literature review of clinical therapy trials using high-dose systemic radioactivity.
  • Analysis of reported radiation absorbed dose estimates to bone marrow and critical organs.

Main Results:

  • Myeloablation is a significant concern in high-dose systemic radiotherapy.
  • Dose estimates to bone marrow are essential for treatment planning and dose escalation.
  • Toxicity in other organs necessitates accurate dose assessment for future study design.

Conclusions:

  • Accurate assessment of radiation absorbed dose is vital for optimizing high-dose systemic radiotherapy.
  • Individualized treatment planning and future study designs can benefit from improved dosimetry.
  • Minimizing toxicity while maximizing therapeutic effect requires precise radiation dose evaluation.

Related Experiment Videos